Investors

Explore how Hikma’s diversified portfolio, operational excellence, and global reach delivers value for investors

Hikma released its financial results for the year ended 31 December 2025 on Thursday 26 February 2026.
Latest news

Newsroom

All news stories

Hikma delivers a solid H1 performance and reiterates full year outlook

Press Release, Financial Results

Hikma launches Sugammadex Injection in a prefilled syringe in the US

Press Release, Product

Inspired at Hikma: Purpose-driven leadership, developing talent and building for growth. Meet Kristy Ronco

Story, Life at Hikma

Hikma launches Diazepam Injection, USP in the US

Press Release, Product

Hikma launches XCOPRI® (Cenobamate tablets) in the UAE

Press Release, Product

Hikma welcomes FDA approval of Guardant360® Liquid CDx

Press Release, Product

Behind Better Health: Hikma's People

Insight, Life at Hikma

Hikma comments on Supreme Court of the United States’ unanimous decision in favour of Hikma

Press Release, Corporate

Hikma Pharmaceuticals puts access to medicines at the heart of its sustainability strategy, reaching 222 million patient...

Press Release, Corporate

Hikma launches Tofacitinib oral solution in the US

Press Release, Product
Sign up here if you would like to receive email alerts with our latest results, regulatory news, and business updates.
Stay informed